Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Mar 28;121(13):2567-73.
doi: 10.1182/blood-2012-08-453860. Epub 2013 Jan 29.

Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

Affiliations
Multicenter Study

Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

Amin M Alousi et al. Blood. .

Abstract

Older patients are increasingly undergoing allogeneic hematopoietic transplantation. A relevant question is whether outcomes can be improved with a younger allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched sibling (MSD). Accordingly, transplants in leukemia/lymphoma patients age ≥50 years were analyzed comparing outcomes for recipients of MSD ≥50 (n = 1415) versus MUD <50 years (n = 757). Risks of acute graft-versus-host disease (GVHD) grade 2 to 4 (hazard ratio [HR], 1.63; P < .001), 3 to 4 (HR, 1.85; P < .001), and chronic GVHD (HR, 1.48; P < .0001) were higher after MUD compared with MSD transplants. The effect of donor type on nonrelapse mortality (NRM), relapse, and overall mortality was associated with performance score. For patients with scores of 90 or 100, NRM (HR, 1.42; P = .001), relapse (HR, 1.45; P < .001), and overall mortality (HR, 1.28; P = .001) risks were higher after MUD transplants. For patients with scores below 90, NRM (HR, 0.96; P = .76), relapse (HR, 0.86; P = .25), and overall mortality (HR, 0.90; P = .29) were not significantly different after MUD and MSD transplants. These data favor an MSD over a MUD in patients age ≥50 years.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The probabilities of acute and chronic GVHD, non-relapse mortality, and overall survival. (A)The unadjusted cumulative incidence of grade 2 to 4 acute GVHD for recipients of MSD transplants with donors age 50 years or older and MUD transplants with donors age younger than 50 years. (B) The unadjusted cumulative incidence of chronic GVHD for recipients of MSD transplants with donors age 50 years or older and MUD transplants with donors age younger than 50 years. (C) The unadjusted cumulative incidences of NRM for recipients of MSD transplants with donors age 50 years or older and performance scores 90 or 100 (group A), MSD transplants with donors age 50 years or older and performance scores 80 or lower (group B), MUD transplants with donors age younger than 50 years and performance scores 90 or 100 (group C) and MUD transplants with donors age younger than 50 years and performance scores 80 or lower (group D). (D) Probabilities of OS adjusted for conditioning regimen, patient age, disease, and disease status for recipients of MSD transplants with donors age 50 years or older and performance scores 90 or 100 (group A), MSD transplants with donors age 50 years or older and performance scores 80 or lower (group B), MUD transplants with donors age younger than 50 years and performance scores 90 or 100 (group C) and MUD transplants with donors age younger than 50 years and performance scores of 80 or lower (group D).

Similar articles

Cited by

References

    1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2011. http://www.cibmtr.org.
    1. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med. 2001;345(25):1794–1800. - PubMed
    1. Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010;116(11):1839–1848. - PMC - PubMed
    1. Liu QF, Xu XJ, Chen YK, et al. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Ann Hematol. 2011;90(3):331–341. - PubMed
    1. Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007;13(5):601–607. - PubMed

Publication types